ProMIS Neurosciences Croissance future

Future contrôle des critères 0/6

ProMIS Neurosciences devrait augmenter son chiffre d'affaires de 84.6% par an.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	42.4%
Taux de croissance des recettes	84.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	14 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

DB:23J0 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	N/A	N/A	N/A	2
12/31/2025	N/A	N/A	N/A	N/A	2
12/31/2024	N/A	-2	N/A	N/A	2
9/30/2024	N/A	-1	-22	-22	N/A
6/30/2024	N/A	-12	-18	-18	N/A
3/31/2024	N/A	-12	-19	-19	N/A
12/31/2023	N/A	-13	-11	-11	N/A
9/30/2023	N/A	-17	-12	-12	N/A
6/30/2023	N/A	-20	-14	-14	N/A
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	N/A	-13	-17	-17	N/A
6/30/2022	N/A	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	N/A	-5	N/A
3/31/2018	0	-5	N/A	-5	N/A
12/31/2017	0	-5	N/A	-5	N/A
9/30/2017	0	-5	N/A	-4	N/A
6/30/2017	0	-4	N/A	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 23J0 est supérieure au taux d'épargne ( 1% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 23J0 devraient croître plus rapidement que le marché German

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 23J0 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: 23J0 ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: 23J0 ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 23J0 devrait être élevé dans 3 ans

ProMIS Neurosciences Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Revenue in line with expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

First half earnings released

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance